Skip to main content
Equibles

SUNPHARMA · Sun Pharmaceutical Industries Limited · Financials

Use SUNPHARMA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SUNPHARMA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1,885.00 INR -17.30 (-0.91%) At close · Nov 12
Rebalance outlook locked
Market Cap
4.52T INR
Shares
2.40B
Volume · Nov 12 2.46M Avg daily vol (3M) 1.77M

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
584.62B +11.2%
FY2026 Revenue FY2018–FY2026
Net Income
114.79B +5%
FY2026 Net Income FY2018–FY2026
Operating Cash Flow
124.19B -11.7%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
INR 616.31B 584.62B 525.78B 484.97B 438.86B 386.54B 334.98B 328.38B 290.66B 264.89B
INR 30.05B 29.38B 25.75B 25.57B 25.29B 21.44B 20.8B 20.53B 17.53B 15B
INR 3.39B 3.39B 2.31B 2.38B 1.72B 1.27B 1.41B 3.03B 5.55B 5.18B
INR 39.99B 35.54B 27.72B 14.39B 8.48B 10.76B 5.15B 8.23B 6.01B 8.45B
INR 109.66B 114.79B 109.29B 95.76B 84.74B 32.73B 29.04B 37.65B 26.65B 21.62B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 151.45B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.